SCHEMBL5465327

SCHEMBL5465327

O=C(Nc1nccc(-c2cccc(Br)c2)n1)c1cccs1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.65
SMN1; SMN2 Q16637 5/20 0.65
NPC1 O15118 4/20 0.65
RAB9A P51151 4/20 0.65
GAA P10253 2/20 0.65
ABL1 P00519 1/20 0.60
PDGFRB P09619 1/20 0.60
SRC P12931 1/20 0.60
PDGFRA P16234 1/20 0.60
LMNA P02545 3/20 0.49
MAPT P10636 4/20 0.48
KDM4E B2RXH2 4/20 0.48
HPGD P15428 3/20 0.48
GLA P06280 1/20 0.48
POLB P06746 1/20 0.48
MEN1 O00255 5/20 0.47
KMT2A Q03164 5/20 0.47
HTT P42858 3/20 0.47
PKM P14618 2/20 0.47
TP53 P04637 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5472912 0.86 RAB9A (0.74) ALDH1A1SMN1; SMN2NPC1RAB9AGAA
SCHEMBL5463021 0.84 ABL1 (0.66) ALDH1A1SMN1; SMN2NPC1RAB9AGAA
SCHEMBL5464069 0.84 ALDH1A1 (0.61) ALDH1A1SMN1; SMN2NPC1RAB9AGAA
SCHEMBL5466020 0.83 RAB9A (0.67) ALDH1A1SMN1; SMN2NPC1RAB9AGAA
SCHEMBL5471802 0.83 RAB9A (0.60) ALDH1A1SMN1; SMN2NPC1RAB9AGAA
SCHEMBL5462697 0.81 ALDH1A1 (0.58) ALDH1A1ABL1PDGFRBSRCPDGFRA
SCHEMBL5465929 0.80 NPC1 (0.70) ALDH1A1SMN1; SMN2NPC1RAB9AGAA
SCHEMBL5467105 0.80 RAB9A (0.70) ALDH1A1SMN1; SMN2NPC1RAB9AGAA
SCHEMBL5473477 0.80 NPC1 (0.70) ALDH1A1SMN1; SMN2NPC1RAB9AGAA
SCHEMBL5465340 0.79 ALDH1A1 (0.61) ALDH1A1SMN1; SMN2NPC1RAB9AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070099938-A1 Antistress drug and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-05-03 US disclosed
EP-1679309-A1 ANTISTRESS DRUG AND MEDICAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099938-A1 Antistress drug and medical use thereof NPSR1, MC2R, SRR ALDH1A1 2447/4885SMN1; SMN2 2306/4885NPC1 1950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.